Rabies Infection Pipeline Insight 2025: Monoclonal Antibodies, Novel Vaccines, and Antiviral Platforms Drive Innovation | DelveInsight

The therapeutic pipeline for rabies is steadily advancing, with new approaches aiming to enhance prevention and post-exposure care. While current PEP with vaccines and immunoglobulin is effective if given promptly, limited access, high costs, and lack of treatment for symptomatic cases underscore a significant unmet need.
DelveInsight's "Rabies Infection - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/rabies-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" showcases a growing portfolio of candidates targeting both pre- and post-symptomatic stages. Recombinant monoclonal antibody cocktails are being developed as scalable, safer alternatives to RIG, offering consistent potency and reduced cold chain dependency. Next-generation vaccines-including vector-based, nucleic acid-based (mRNA, DNA), and intradermal dose-sparing formulations-are advancing in clinical and late preclinical stages to enhance immunogenicity, durability, and accessibility in endemic regions. Antiviral platforms, including RNA polymerase inhibitors and virus-neutralizing peptides, are under investigation to extend the therapeutic window after exposure and potentially treat early symptomatic rabies.

The 2025 rabies pipeline reflects a strategic shift toward globally deployable, precision-targeted prevention and treatment modalities. With growing global health prioritization, regulatory encouragement for innovative biologics, and increased funding from public-private partnerships, the next wave of rabies research holds promise to bridge the gap between prevention and cure-moving beyond reactive care toward durable, universal protection.

Interested in learning more about the current treatment landscape and the key drivers shaping the rabies infection pipeline? Click here [https://www.delveinsight.com/report-store/rabies-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Key Takeaways from the Rabies Infection Pipeline Report

- DelveInsight's rabies infection pipeline analysis depicts a strong space with 10+ active players working to develop 10+ pipeline drugs for rabies infection treatment.

- The leading rabies infection companies include Synermore Biologics, Sanofi, Anhui Zhifei Longcom Biopharmaceutical, CureVac AG, Yisheng Biopharma, GlaxoSmithKline, Rabies G protein vaccine, Connectyx Technologies, and others are evaluating their lead assets to improve the rabies infection treatment landscape.

- Key rabies infection pipeline therapies in various stages of development include SYN023, Purified vero rabies vaccine, Freeze-dried Human Rabies Vaccine, CV7201, PIKA rabies vaccine, GSK 3903133A, Rabies G protein vaccine, IMT504, and others.

- In July 2025, the U.S. FDA approved a labeling supplement for IMOVAX Rabies to add a 2-dose pre-exposure prophylaxis (PrEP) regimen (in addition to the 3-dose schedule), referencing NCT03700242 and NCT04127786.

- In July 2024, npj Vaccines reported multi-species efficacy data for a non-replicating mRNA rabies vaccine protecting dogs, rodents, and macaques-supporting continued clinical development (published July 20, 2024).

- In June 2025, a Phase III, randomized, double-blind trial reported that SYN023 (zamerovimab + mazorelvimab) used for post-exposure prophylaxis achieved superior Day-8 RVNA titers vs HRIG with no rabies cases, published online ahead of print in Vaccine on June 5, 2025.

- In May 2025, npj Vaccines published an observational clinical study (n=159) showing a favorable safety profile for the docaravimab/miromavimab monoclonal antibody cocktail (TwinRab) used in severe animal bites for rabies PEP, with no rabies cases over 6 months of follow-up (published May 21, 2025).

- In July 2024, npj Vaccines reported multi-species efficacy data for a non-replicating mRNA rabies vaccine protecting dogs, rodents, and macaques-supporting continued clinical development (published July 20, 2024).

Rabies Infection Overview

Rabies infection is a viral disease caused by the rabies virus, primarily transmitted through the bite or scratch of an infected animal. It affects the central nervous system, leading to inflammation of the brain (encephalitis) and, if untreated, is almost always fatal. Early symptoms include fever, headache, and general weakness, progressing to more severe signs such as anxiety, confusion, paralysis, and hydrophobia (fear of water). The virus travels from the entry site to the brain via the peripheral nerves, making timely post-exposure prophylaxis (PEP) critical to preventing disease onset. Rabies remains a significant public health concern worldwide, especially in regions with limited access to vaccines and healthcare.

Prevention of rabies primarily involves vaccination of domestic animals, wildlife control, and prompt administration of rabies vaccines and immunoglobulins after potential exposure. Current treatments include various rabies vaccines, such as purified vero rabies vaccine and novel candidates like SYN023 and PIKA rabies vaccine, which are designed to enhance immune response and improve protection. Despite advances in vaccine development, rabies continues to cause thousands of deaths annually, emphasizing the need for increased awareness, vaccination programs, and access to medical care.

Find out more about rabies infection medication at https://www.delveinsight.com/report-store/rabies-infection-pipeline-insight [https://www.delveinsight.com/report-store/rabies-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Rabies Infection Treatment Analysis: Drug Profile

SYN-023: Synermore Biologics

SYN-023, developed by Synermore Biologics, is a combination of two humanized monoclonal antibodies, CTB-011 and CTB-012, that target two distinct antigenic sites on the rabies glycoprotein. Intended for post-exposure prophylaxis in humans alongside the rabies vaccine, SYN-023 works by binding to the rabies virus and neutralizing it, mimicking the natural immune response. It has demonstrated the ability to neutralize over 15 contemporary rabies virus isolates from wildlife in China and 10 isolates from North America. Currently, SYN-023 is in Phase III clinical trials for the treatment of rabies infection.

Freeze-dried human rabies vaccine: Anhui Zhifei Longcom Biopharmaceutical

The freeze-dried human rabies vaccine, developed by Anhui Zhifei Longcom Biopharmaceutical, utilizes Vero cells and is also in Phase III development for rabies treatment.

Learn more about the novel and emerging rabies infection pipeline therapies [https://www.delveinsight.com/report-store/rabies-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr].

Rabies Infection Therapeutics Assessment

By Product Type

- Mono

- Combination

- Mono/Combination.

By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

By Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

By Molecule Type

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

Scope of the Rabies Infection Pipeline Report

- Coverage: Global

- Key Rabies Infection Companies: Synermore Biologics, Sanofi, Anhui Zhifei Longcom Biopharmaceutical, CureVac AG, Yisheng Biopharma, GlaxoSmithKline, Rabies G protein vaccine, Connectyx Technologies, and others.

- Key Rabies Infection Pipeline Therapies: SYN023, Purified vero rabies vaccine, Freeze-dried Human Rabies Vaccine, CV7201, PIKA rabies vaccine, GSK 3903133A, Rabies G protein vaccine, IMT504, and others.

Explore detailed insights on drugs used in the treatment of rabies infection here [https://www.delveinsight.com/report-store/rabies-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr].

Table of Contents

1. Introduction

2. Executive Summary

3. Rabies Infection Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Rabies Infection Pipeline Therapeutics

6. Rabies Infection Pipeline: Late-Stage Products (Phase III)

7. Rabies Infection Pipeline: Mid-Stage Products (Phase II)

8. Rabies Infection Pipeline: Early Stage Products (Phase I)

9. Therapeutic Assessment

10. Inactive Products

11. Company-University Collaborations (Licensing/Partnering) Analysis

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rabies-infection-pipeline-insight-2025-monoclonal-antibodies-novel-vaccines-and-antiviral-platforms-drive-innovation-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.